The purpose of this paper is to present the study protocol and results of a validation substudy for a planned retrospective cohort study of the safety and effectiveness of erlotinib and gefitinib during the first decade of their use in NZ for treating advanced EGFR mutation–positive lung cancer. This evidence concerns the gene EGFR and lung carcinoma.